Clinical trial
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal…
NCT00138125 · Translational Oncology Research International, Other · Terminated
Key facts
| NCT number | NCT00138125 |
|---|---|
| Title | Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer |
| Official title | Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | University of California, Los Angeles Genentech, Inc. Industry AstraZeneca |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | Faslodex, Herceptin |
| Enrollment | 2 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Aug 30, 2005 |
| Last update posted | Oct 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: